Biologics CDMO Market by Deployment, by Applications, by Type, by End-User & by Technology 2032
Global Biologics CDMO Market was valued at USD 1.5 Billion in 2022 and is projected to reach USD 3.0 Billion by 2030, growing at a CAGR of 9.6% from 2024 to 2030.
The biologics CDMO (Contract Development and Manufacturing Organization) market is rapidly growing, driven by the increasing demand for biologic drugs and the need for efficient, scalable manufacturing solutions. As more biopharma companies move towards biologics, the market for contract manufacturing and development services has seen a significant boom. The biologics CDMO market is projected to grow substantially over the next few years, with new players entering the space and established companies expanding their capabilities.
The global biologics CDMO market offers a diverse range of services, including drug development, formulation, clinical trials, and commercial manufacturing. A major factor contributing to the market's growth is the increasing prevalence of chronic diseases and the subsequent demand for innovative treatments. Biologic drugs, such as monoclonal antibodies, vaccines, and gene therapies, are considered to be a cornerstone of modern medicine, and their complexity requires specialized manufacturing expertise. This is where CDMOs come in, providing the expertise, infrastructure, and resources necessary for bringing biologics to market efficiently.
One of the key trends in this market is the growing importance of outsourcing to mitigate costs, reduce development timelines, and meet regulatory requirements. Biopharma companies increasingly rely on CDMOs to handle the complexity of biologic manufacturing, which includes production at scale, quality assurance, and ensuring compliance with Good Manufacturing Practices (GMP). Additionally, the shift toward personalized medicine and rare disease treatments is pushing for more flexibility in production capabilities, which many CDMOs are now equipped to handle.
The competition in the biologics CDMO market is fierce, with both established pharmaceutical companies and specialized players vying for market share. Partnerships, acquisitions, and mergers are becoming common as companies look to expand their service offerings and global reach. The rise of biologic drugs, coupled with advancements in biotechnology and manufacturing technologies, is expected to continue driving growth in the sector.
Get an In-Depth Research Analysis of the Global Biologics CDMO Market Size And Forecast [2025-2032]
Who are the largest Global manufacturers in the Biologics CDMO industry?
- Lonza Group AG
- Samsung Biologics
- AbbVie
- WuXi Biologics
- Toyobo
- AGC
- Thermo Fisher Scientific
- ICON Plc
- Boehringer Ingelheim
- Fujifilm Diosynth Biotechnologies
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Biologics CDMO Market Size And Forecast [2025-2032]
What are the factors driving the growth of the Global Biologics CDMO Market?
Growing demand for below applications around the world has had a direct impact on the growth of the Global Biologics CDMO Market
- Cell Therapy
- Drug Development
- Others
What are the types of Biologics CDMO available in the Market?
Based on Types the Market is categorized into Below types that held the largest Biologics CDMO market share In 2023.
- Biological Agent
- Biosimilar Drug
Which regions are leading the Global Biologics CDMO Market?
- Global (United States, Global and Mexico)
- Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
- Asia-Pacific (China, Global, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
- South America (Brazil, Argentina, Columbia, etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Biologics CDMO Market Research Analysis
Detailed TOC of Global Biologics CDMO Market Research Report, 2024-2032
1. Introduction of the Global Biologics CDMO Market
- Overview of the Market
- Scope of Report
- Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
- Data Mining
- Validation
- Primary Interviews
- List of Data Sources
4. Global Biologics CDMO Market Outlook
- Overview
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Porters Five Force Model
- Value Chain Analysis
5. Global Biologics CDMO Market, By Type
6. Global Biologics CDMO Market, By Application
7. Global Biologics CDMO Market, By Geography
- Global
- Europe
- Asia Pacific
- Rest of the World
8. Global Biologics CDMO Market Competitive Landscape
- Overview
- Company Market Ranking
- Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768